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clinical case report
Novel DMRT1 3’UTR+11insT 
mutation associated to XY 
partial gonadal dysgenesis
Nova mutação 3’UTR+11insT no gene DMRT1 
associada à disgenesia gonadal parcial XY
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SUMMARY
The Y-chromosome-located SRY gene encodes a small testis-specific protein containing a DNA-
-binding motif known as the HMG (high mobility group) box. However, mutations in SRY are 
not frequent especially in cases of 46,XY partial gonadal dysgenesis. Several sex-determining 
genes direct the fate of the bipotential gonad to either testis or ovary. In addition, heterozygous 
small deletions in 9p can cause complete and partial XY gonadal dysgenesis without other 
symptoms. Human DMRT1 gene, which is located at 9p24.3, is expressed in testis and ovary 
and has been considered, among others, a candidate autosomal gene responsible for gonadal 
dysgenesis. In this report we describe a nucleotide insertion in DMRT1 3’UTR in a patient of XY 
partial gonadal dygenesis. The 3’UTR+11insT is located within a conserved motif important for 
mRNA stabilization. Arq Bras Endocrinol Metab. 2010;54(8):749-53
SUMáRio
O gene SRY, localizado no cromossomo Y, codifica uma proteína testículo-específica conten-
do um domínio HMG (grupo de alta mobilidade) de ligação ao DNA. No entanto, mutações 
no gene SRY não são frequentes, especialmente nos casos de disgenesia gonadal parcial em 
indivíduos 46,XY. São atualmente conhecidos vários genes que participam do processo de di-
ferenciação gonadal, tanto para o desenvolvimento testicular quanto para o ovariano. Além 
disso, pequenas deleções heterozigotas em 9p podem causar disgenesia gonadal XY completa 
ou parcial, sem outros sintomas associados. O gene DMRT1 humano, que está localizado em 
9p24.3, é expresso no testículo e ovário no período fetal e tem sido considerado um dos genes 
autossômicos envolvido na etiologia das disgenesias gonadais. Neste trabalho, descrevemos a 
inserção de um nucleotídeo em 3’UTR do gene DMRT1 em um paciente 46,XY com disgenesia 
gonadal parcial. A mutação 3’UTR+11insT está localizada dentro de um motivo conservado 
importante para a estabilização do mRNA. Arq Bras Endocrinol Metab. 2010;54(8):749-53
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iNTRoDUCTioN
Disorders of sex development (DSD) are defined as congenital conditions in which development 
of chromosomal, gonadal, or anatomical sex is atypi-
cal (1). XY gonadal dysgenesis (OMIM ID #400044) 
is a DSD in which the embryonic gonadal development 
is defective (2). Clinically, XY gonadal dysgenesis may 
manifest as complete or partial forms. Complete go-
nadal dysgenesis in 46,XY individuals is characterized 
by a female phenotype with full development of un-
ambiguous female genitalia, normally developed Mül-
lerian structures, and streak gonads. In general, these 
patients come for clinical assistance because of delayed 
puberty (3). Conversely, 46,XY partial gonadal dysgen-
esis is characterized by partial testicular differentiation 
therefore ambiguous genitalia is usually observed in the 
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newborn period. Gonadal histology is variable but fre-
quently consists of hypoplastic testicular tubules inter-
mixed with areas of ovarian stroma (4). Internal ducts 
typically consist of a combination of Wolffian and Mul-
lerian ducts (4). 
The failure in testis development may be a conse-
quence of mutations in the SRY gene (5). The Y-chro-
mosome-located SRY gene encodes a small testis-spe-
cific protein containing a DNA-binding motif known 
as the HMG (high mobility group) box. However, mu-
tations in SRY are not frequent especially in cases of 
46,XY partial gonadal dysgenesis (6,7). 
Several sex-determining genes direct the fate of 
the bipotential gonad to either testis or ovary (8). It 
is well known that heterozygous small deletions in 
9p can cause complete or partial XY gonadal dysgen-
esis (OMIM ID #154230) without other symptoms 
(9,10). A human gene located at 9p24.3 with sequence 
similarities to genes that regulate sexual development 
in insects and nematodes has been described as respon-
sible for XY gonadal dysgenesis. This gene is called 
DMRT1 (doublesex and mab-3 related transcription 
factor 1) and in adults it is expressed in the testis and 
ovary (11,12). The gene has five exons and is predicted 
to encode a protein of 373 amino acids with a DM do-
main near its N-terminal portion (13). There are four 
DMRT1 mutations in codons 45, 221, 281, and 295, 
but their association to a characteristic 46,XY gonadal 
dysgenesis phenotype is not well defined (13).
We report here a DMRT1 nucleotide insertion in 
3’UTR found by sequence analysis in a case of XY par-
tial gonadal dygenesis. The 3’UTR+11insT is located 
within a conserved motif important for directing alter-
native splicing and/or promoting mRNA stabilization.
SUBJECT AND METHoDS
Blood specimens and clinical data of the patient and 
relatives were collected with approval by the appropri-
ate Institutional Review Board; signed informed con-
sent was obtained.
Clinical data 
A 7-month-old male infant was referred to us due to sex 
ambiguity. The child was delivered by cesarean section 
after an uneventful 39-week pregnancy. Birth weight 
was 3,100 g and length 48 cm. He was the second child 
of young healthy unrelated parents. When first exam-
ined by us, weight was 6,820 g and length 65.1 cm. 
There was no dysmorphic picture, and genital examina-
tion revealed a 2.3 cm phallus with chordee, penoscro-
tal hypospadias, scrotum with rugae and pigmentation, 
and both gonads were palpable at inguinal region with 
1.0 cm at the greatest diameter. Hormonal evaluation 
at the age of 7 months revealed normal gonadotropin 
levels (FSH = 3.1 IU/L, normal range (NR) = 1.5-
12.4 IU/L; LH = 0.1 IU/L, NR = 1.7-8.6 IU/L), 
low levels of total testosterone (after 3 days of 1,500 
IU of hCG per day) (0.02 ng/mL, NR > 1.5 ng/mL) 
and anti-müllerian hormone (114 pMol/L, NR = 265-
679 pMol/L), but also normal values of ACTH (21 
pg/mL, NR < 46 pg/mL), cortisol (12 μg/dL, NR = 
5-25 μg/dL), progesterone (0.7 ng/mL, NR = 0.1-
1.4 ng/mL), 17-OH progesterone (0.8 ng/mL, NR = 
0.2-1.5 ng/mL), androstenedione (1.0 ng/mL, NR = 
0.7-3.6 ng/mL) and DHEA (3.7 ng/mL, NR = 3.0-
6.1 ng/mL). G-banding karyotype in 32 cells revealed 
a 46,XY karyotype. After three injections of testoster-
one enanthate (50 mg over successive months), phallus 
size increased 2 cm. The diagnosis of 46,XY DSD due 
to partial gonadal dysgenesis was confirmed by biopsy 
of both gonads, which revealed bilateral prepubertal 
testis with marked tubular hypoplasia, severe germinal 
hypoplasia and Sertoli cells hyperplasia. This patient is 
patient number 5 of the paper published by Ribeiro-
Scolfaro and cols. (4). 
Molecular analysis
Genomic DNA was extracted from peripheral blood 
leukocytes by the standard phenol/chloroform method. 
For the microdeletion investigation, the following 
polymorphic markers located in the distal part of 9p: 
D9S143 (14); D9S1779, D9S1858, D9S1813, and 
D9S54 (http://www.ensembl.org/Homo_sapiens/
index.html) were used. Each microsatellite was ampli-
fied in an independent radioactive PCR. PCR was per-
formed in a final volume of 12.5 µL containing 50-100 
ηg of genomic DNA, 20 ρmol of each primer, 200 M 
of each dNTPs (0.2 mM dATP + 0.2 mM dTTP + 0.2 
mM dGTP + 0.1 mM dCTP + 1 μCi [α-32P] dCTP), 
0.25 U Taq DNA polymerase (Invitrogen, CA, USA) 
reaction buffer for the enzyme, 1.0 mM to 1.5 mM 
MgCl2. PCR cycles were: 94
oC for 5 minutes, 94oC for 
30 seconds, 57oC for 30 seconds, 72oC for 30 seconds 
(25 cycles) and a final step of 72oC for 5 min. Radio-
active PCR products were mixed in a loading buffer 
containing 95% formamide, 0.05% bromophenol blue, 
20 mM EDTA, and pH 8.0. Then the samples were 
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denatured for 5 minutes at 94oC and applied to dena-
turing polyacrylamide gel 6%. Electrophoresis was per-
formed at 1500 V, 50 W, 50 mA, for 2-4 hours. Gels 
were placed in a gel dryer for an hour and then exposed 
to X-ray films (Hyperfilm MP − Amersham-Pharmacia 
Biotech) at -70°C for 2-8 hours.
DMRT1 gene was amplified by PCR amplifica-
tion of the entire coding region including exon-intron 
junctions and both 5’UTR and 3’UTR regions us-
ing synthetic oligonucleotides (Invitrogen) as primers 
(Table 1) which were designed using Primer 3 open 
access software (http://primer3.sourceforge.net). The 
amplified fragments were directly sequenced using Big 
Dye TM Terminator Cycle Sequencing Kit V3.1 Ready 
Reaction (ABI PRISM/PE Biosystems, Foster City, 
CA, USA). The sequences obtained in an ABI3700 
Automated Sequencer (ABI PRISM/PE Biosystems) 
were compared to the normal sequence of the gene 
(ENSG00000137090).
RESULTS
To investigate the possibility of a 9p deletion in the pa-
tient, a study using DNA microsatellite in the critical in-
terval 9p24.3 was carried out. There was no evidence of 
microdeletion in the DMRT1 region because the patient 
was heterozygous for all microsatellite tested, but D9S54. 
DMRT1 sequence analysis on the patient’s DNA re-
vealed the heterozygous insertion of a thymine located 
12 nucleotides beyond the stop codon in the 3’UTR 
(Figure 1). Sequencing also revealed heterozygosity for 
a nucleotide change T>A in exon 1 that caused p.S45T 
protein variation (data not shown), considered to play 
no biological effect on protein function, therefore a 
polymorphism (rs16925431-dbSNP125). Unfortu-
nately, parents were not available to evaluate the segre-
gation of both allelic variants.
Table 1. Primers for DMRT1 gene amplification and sequencing
Primer Sequence (5 → 3’) Tm (°C)
E1FA CTC CGG AGC GTC GCT GTC CGT CGG 63
EIRA GAG CCA AGA TCG CGC CAC TAC ACT GC 59
E1FS TCC CTG GCA GCA GTC TCC AGG CGA G 61
E1RS AGC CTG GCA ACC GAG CGA GAC TC 57
E2FS GTG TTT TGG CAA AGC TGA TTC TGG 51
E2RS TGC AAC CTT CGG CCT CCC TCA TGC 57
E3FS AGA AGT AAA GTT TCG TGG ACT AAC 47
E3RS TGC ACA TGC ATG TGG CTT TCA CAC 52
E4F CAC TGT GCC CAG CCT GTT ACC TTG 56
E4R AAG CCA TTA GAC ACA GCT AAT GAC 49
E5F GAA TAA TGA ATG TAT AAA GAC CAG CCA C 50
CR64 CAG CCT CTG GAC TAA ACT CTA AGG 52
CR76 GGC AAA GCG TCT GGG GCG CTA GTG 59
Figure 1. Eletropherograms showing the end of exon 5 and part of 3’UTR of DMRT1 gene. (A) normal sequence. (B) Heterozygosis for a T insertion in the patient’s 
sample; the red arrow indicates the insertion site. (C) Sequence alignment: sequence on the top shows the normal allele, in the middle, 3’UTR+11insT, and at the 
bottom sequencing reading of the heterozygous patient; the stop codon TGA is underlined. (K) = G or T; (M) = A or C; (S) = G or C; (Y) = C or T; (W) = A or T.
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DiSCUSSioN
A novel insertion in DMRT1 gene was identified in the 
patient described here with 46,XY partial gonadal dys-
genesis. SRY and WT1 genes were studied before but 
the patient did not carry mutations in either gene (7). 
Therefore, deletions and mutations on 9p and DMRT1 
gene, respectively, were investigated.
Recent studies on DMRT1 gene have shown a very 
complex pattern of expression in male gonads involving 
the production of alternative transcripts in both mice and 
humans (15,16). Cheng and cols. (15) have character-
ized multiple transcript isoforms in human testis. These 
transcripts code for different putative proteins, two of 
them generated by alternative splicing in the 3’UTR. 
Other transcripts are results of the intronic exonization 
including Alu elements that are not randomly distribut-
ed in the non-coding regions. In mice, alternative splic-
ing processes were detected in adult testis and in undif-
ferentiated gonads. All forms are produced with a similar 
pattern of expression peaking at 13.5 days after fertiliza-
tion and maintaining a baseline pattern of expression in 
male gonads (16). These experiments indicate an impor-
tant role of this gene in the testicular determination and 
differentiation in mammals. The genomic region where 
the 3’UTR+11insT mutation occurred is recognized as 
an Exonic Splicing Enhancer by PSEX (Putative Exonic 
Splicing Enhancers/Silencers) algorithm (17,18). A pre-
liminary in silico analysis using ESEfinder 3.0 to identify 
exonic splicing enhancers (19,20) indicates the abolish-
ment of a SC35 protein recognition site in the presence 
of the 3’UTR+11insT mutation. 
Herpin and cols. (21) studied mechanisms that reg-
ulate the expression of specific genes in the gonads dur-
ing embryonic development. They found the protein-
binding conserved motif CUGCUGCCGAU located 
in the DMRT1 3’UTR that participates in the gonad-
specific stabilization of mRNA during development. 
The presence of this sequence indicates the importance 
of cis and trans elements forming mRNA-protein com-
plexes in the control of specificity and selectivity of 
gene expression. The insertion described here is located 
exactly in the middle of the highly conserved region 
changing this sequence to CUGCUUGCCGAU. 
In conclusion, the mutation identified in the patient 
with partial gonadal disgenesis may cause the pheno-
type either by modifications in the alternative splicing 
process or by preventing mRNA stabilization by pro-
tein binding and, consequently, leading to mRNA deg-
radation. 
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